By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ironwood Pharmaceuticals 

301 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-7722 Fax: 617-494-0480


SEARCH JOBS

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.


Key Statistics


Email:
Ownership: Public

Web Site: Ironwood
Employees:
Symbol: IRWD
 



Industry
Pharmaceutical






Company News
Ironwood (IRWD), Aegerion (AEGR), and MannKind Corporation (MNKD) Face Stiff Headwinds: Analyst 8/17/2015 7:14:37 AM
Ironwood (IRWD) Provides Second Quarter 2015 Investor Update 8/6/2015 11:46:33 AM
Ironwood (IRWD) And Allergan (AGN) Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S. 8/5/2015 11:21:49 AM
Ironwood (IRWD) Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973 7/22/2015 10:15:00 AM
Ironwood (IRWD) To Host Second Quarter 2015 Investor Update Call 7/16/2015 12:08:04 PM
EXCLUSIVE: Ironwood (IRWD), AstraZeneca PLC (AZN) IBS-C Drug Will File in China Next Year, CEO Tells BioSpace (DHX) 7/9/2015 4:30:54 PM
AstraZeneca PLC (AZN) And Ironwood (IRWD) Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China 7/8/2015 8:19:51 AM
Ironwood (IRWD) Prices $300 Million of Convertible Senior Notes 6/10/2015 9:05:36 AM
Ironwood (IRWD) Announces Proposed Offering Of $300 Million Of Convertible Senior Notes 6/9/2015 12:10:44 PM
Ironwood (IRWD) To Present At Goldman, Sachs & Co. 36th Annual Global Healthcare Conference 6/5/2015 7:44:06 AM
12345678910...
//-->